EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Mecapegfilgrastim for the prophylaxis of chemotherapy‐induced neutropenia in locally advanced nasopharyngeal carcinoma: A prospective phase II clinical study

Qifeng Jin, Yonghong Hua, Ting Jin, Lei Wang, Changjuan Tao, Shuang Huang, Weifeng Qin, Xiaozhong Chen iD

Head & Neck · 2025

DOI: 10.1002/hed.27897 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Head & Neck, 2025. Verfasst von Qifeng Jin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China. Hauptthemen laut MEDLINE: Nasopharyngeal Neoplasms, Nasopharyngeal Carcinoma, Neutropenia, Docetaxel. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Induction chemotherapy of docetaxel plus cisplatin (TP) is myelosuppressive, leading to severe neutropenia and febrile neutropenia (FN). Herein, we aimed to investigate the efficacy and safety of mecapegfilgrastim in the prevention of neutropenia in patients with locally advanced nasopharyngeal carcinoma who received the TP regimen.

Methods

A total of 30 treatment‐naive patients with locally advanced nasopharyngeal carcinoma were included in this study. Mecapegfilgrastim 6 mg was injected 24–48 h after the completion of induction chemotherapy with the TP regimen.

Results

The incidence of grade ≥3 neutropenia during the three induction chemotherapy cycles was 6.7% (95% CI, 0.8%–22.1%). In the first cycle of chemotherapy, the incidence of grade ≥3 neutropenia was 3.3% (95% CI, 0.1%–17.2%). No FN or antibiotic usage was reported. All 30 patients completed the induction chemotherapy cycles.

Conclusion

Mecapegfilgrastim effectively reduced the incidence of chemotherapy‐induced neutropenia and FN in patients with locally advanced nasopharyngeal carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasopharyngeal NeoplasmsNasopharyngeal CarcinomaNeutropeniaDocetaxelInduction ChemotherapyAntineoplastic Combined Chemotherapy ProtocolsCisplatinHumansMaleFemaleMiddle AgedProspective StudiesAdultFilgrastimAgedTreatment OutcomeNeoplasm Staging

Stichwörter der Autor:innen

PEG‐rhG‐CSFinduction chemotherapymecapegfilgrastimnasopharyngeal carcinomaneutropeniaprimary prophylaxis

Substanzen

DocetaxelCisplatinFilgrastim

Autor:innen und Institutionen

  • Department of Head and Neck Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.

ORCID-Profile: Xiaozhong Chen

Zitieren

APA

Jin, Q., Hua, Y., Jin, T., Wang, L., Tao, C., Huang, S., Qin, W., & Chen, X. (2025). Mecapegfilgrastim for the prophylaxis of chemotherapy‐induced neutropenia in locally advanced nasopharyngeal carcinoma: A prospective phase II clinical study. Head & Neck. https://doi.org/10.1002/hed.27897

Vancouver

Jin Q, Hua Y, Jin T, Wang L, Tao C, Huang S, et al. Mecapegfilgrastim for the prophylaxis of chemotherapy‐induced neutropenia in locally advanced nasopharyngeal carcinoma: A prospective phase II clinical study. Head & Neck. 2025. doi:10.1002/hed.27897

BibTeX
@article{Jin2025,
  author = {Jin, Qifeng and Hua, Yonghong and Jin, Ting and Wang, Lei and Tao, Changjuan and Huang, Shuang and Qin, Weifeng and Chen, Xiaozhong},
  title = {Mecapegfilgrastim for the prophylaxis of chemotherapy‐induced neutropenia in locally advanced nasopharyngeal carcinoma: A prospective phase II clinical study},
  journal = {Head & Neck},
  year = {2025},
  doi = {10.1002/hed.27897}
}
Kostenlos starten →